Abstract
Background: Targeted imaging and therapy (theranostics) is a promising approach for the simultaneous improvement of cancer diagnosis, prognosis and management. Therapeutic and imaging reagents are coupled to tumor-targeting molecules such as antibodies, providing a basis for truly personalized medicine. However, the development of antibody–drug conjugates with acceptable pharmaceutical properties is a complex process and several parameters must be optimized, such as the controlled conjugation method and the drug-to-antibody ratio.
Objective: The major aim of this work is to address fundamental key challenges for the development of versatile technology platform for generating homogenous immunotheranostic reagent.
Method: We conjugated the theranostics reagent IRDye700dx to a recombinant antibody fusion protein containing a self-labeling protein (SNAP-tag) which provides a unique reaction site.
Results: The resulting conjugate was suitable for the imaging of cancer cells expressing the epidermal growth factor receptor and demonstrated potent phototherapeutic and imaging activities against them.
Conclusion: Here, we describe a simple, rapid and robust site-directed labeling method that can be used to generate homogeneous immunoconjugate with defined pharmacological properties.
Keywords: Theranostics, SNAP-tag technology, site-directed labeling method, antibody drug conjugate, photodynamic therapy, IRDye700, EGFR.
Anti-Cancer Agents in Medicinal Chemistry
Title:Fine Tuning Antibody Conjugation Methods using SNAP-tag Technology
Volume: 17 Issue: 10
Author(s): Karinna Chouman, Mira Woitok, Radoslav Mladenov, Claudia Kessler, Elmar Weinhold, Gisela Hanz, Rainer Fischer, Ivo Meinhold-Heerlein, Andreas Bleilevens, Gerrit Gresch, Anka Maria Haugg, Felix Zeppernick, Dirk Bauerschlag, Nicolai Maass, Elmar Stickeler, Katharina Kolberg and Ahmad Fawzi Hussain*
Affiliation:
- Department of Gynaecology and Obstetrics University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen,Germany
Keywords: Theranostics, SNAP-tag technology, site-directed labeling method, antibody drug conjugate, photodynamic therapy, IRDye700, EGFR.
Abstract: Background: Targeted imaging and therapy (theranostics) is a promising approach for the simultaneous improvement of cancer diagnosis, prognosis and management. Therapeutic and imaging reagents are coupled to tumor-targeting molecules such as antibodies, providing a basis for truly personalized medicine. However, the development of antibody–drug conjugates with acceptable pharmaceutical properties is a complex process and several parameters must be optimized, such as the controlled conjugation method and the drug-to-antibody ratio.
Objective: The major aim of this work is to address fundamental key challenges for the development of versatile technology platform for generating homogenous immunotheranostic reagent.
Method: We conjugated the theranostics reagent IRDye700dx to a recombinant antibody fusion protein containing a self-labeling protein (SNAP-tag) which provides a unique reaction site.
Results: The resulting conjugate was suitable for the imaging of cancer cells expressing the epidermal growth factor receptor and demonstrated potent phototherapeutic and imaging activities against them.
Conclusion: Here, we describe a simple, rapid and robust site-directed labeling method that can be used to generate homogeneous immunoconjugate with defined pharmacological properties.
Export Options
About this article
Cite this article as:
Chouman Karinna, Woitok Mira, Mladenov Radoslav, Kessler Claudia, Weinhold Elmar, Hanz Gisela, Fischer Rainer, Meinhold-Heerlein Ivo, Bleilevens Andreas, Gresch Gerrit, Haugg Maria Anka, Zeppernick Felix, Bauerschlag Dirk, Maass Nicolai, Stickeler Elmar, Kolberg Katharina and Hussain Fawzi Ahmad*, Fine Tuning Antibody Conjugation Methods using SNAP-tag Technology, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (10) . https://dx.doi.org/10.2174/1871520617666170213123737
DOI https://dx.doi.org/10.2174/1871520617666170213123737 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tumor Physiology and Charge Dynamics of Anticancer Drugs: Implications for Camptothecin-based Drug Development
Current Medicinal Chemistry Roles of miRNA in the Initiation and Development of Colorectal Carcinoma
Current Pharmaceutical Design Ketogenic Diet and Other Dietary Intervention Strategies in the Treatment of Cancer
Current Medicinal Chemistry Dual Induction of Mitochondrial Apoptosis and Senescence in Chronic Myelogenous Leukemia by Myrtucommulone A
Anti-Cancer Agents in Medicinal Chemistry Melatonin and Aromatase in Breast Cancer
Clinical Cancer Drugs Clostridium difficile Infection: Associations with Chemotherapy, Radiation Therapy, and Targeting Therapy Treatments
Current Medicinal Chemistry Genomic Organization and Control of the Grb7 Gene Family
Current Genomics Moxifloxacin-isatin Hybrids Tethered by 1,2,3-triazole and their Anticancer Activities
Current Topics in Medicinal Chemistry 1-Cyclohexylpiperazine and 3,3-Dimethylpiperidine Derivatives as Sigma-1 (σ1) and Sigma-2 (σ2) Receptor Ligands: A Review
Central Nervous System Agents in Medicinal Chemistry New Cathepsin D Inhibitor Library Utilizing Hydroxyethyl Isosteres with Cyclic Tertiary Amines
Medicinal Chemistry Small Regulatory Molecules Acting Big in Cancer: Potential Role of Mito-miRs in Cancer
Current Molecular Medicine Genetic Counseling for Hereditary Breast and Ovarian Cancer Among Puerto Rican Women Living in the United States
Reviews on Recent Clinical Trials Nanoscale Formulations and Diagnostics With Their Recent Trends: A Major Focus of Future Nanotechnology
Current Pharmaceutical Design Structure Based Lead Optimization Approach in Discovery of Selective DPP4 Inhibitors
Mini-Reviews in Medicinal Chemistry Ellipticine, its Derivatives: Re-evaluation of Clinical Suitability with the Aid of Drug Delivery Systems
Current Cancer Drug Targets Sirtuin Family: A Link to Metabolic Signaling and Senescence
Current Medicinal Chemistry High Expression of miR-483-5p Predicts Chemotherapy Resistance in Epithelial Ovarian Cancer
MicroRNA Increased Toxicity of Doxorubicin Encapsulated into pH-Responsive Poly(β-Amino Ester)-Functionalized MCM-41 Silica Nanoparticles
Current Drug Delivery Ipilimumab and Vemurafenib: Two Different Routes for Targeting Melanoma
Current Cancer Drug Targets Structural Insights for Drugs Developed for Phospholipase D Enzymes
Current Drug Discovery Technologies